PT -期刊文章盟Gaisl托马斯盟——Rejmer Protazy AU -泰尔,Sira AU -海丽,莎拉·r . AU - Osswald进行,马丁AU -鲁斯,马格达雷娜盟——布洛赫,康拉德•e . AU,斯特拉德林John r . AU -科勒,马尔科姆TI - cpap疗法的依从性不佳的阻塞性睡眠呼吸暂停的症状:随机,双盲,对照试验援助- 10.1183/13993003.01526 -2019 DP - 2019年1月01 TA -欧洲呼吸杂志PG - 1901526 4099 - //www.qdcxjkg.com/content/early/2019/12/04/13993003.01526 - 2019. -短4100 - //www.qdcxjkg.com/content/early/2019/12/04/13993003.01526 - 2019. -完整的AB -介绍持续正压通气(CPAP)目前治疗阻塞性睡眠呼吸暂停(OSA)患者困倦的选择，然而，坚持治疗往往被认为是不理想的。我们研究了次优的cpap使用对阻塞性睡眠呼吸暂停患者客观和主观睡眠参数的影响。在这项2周、平行、双盲、随机对照试验中，我们招募了中度至重度阻塞性睡眠呼吸暂停(OSA)患者，他们在治疗前白天嗜睡(epworth - sleep - scale [ESS]评分>10分)，且CPAP坚持时间至少12个月(平均每晚使用时间3-4小时)。患者通过最小化CPAP(假性CPAP)或持续CPAP(治疗性CPAP)进行分组。一个具有历史先验的贝叶斯分析计算了优势的后验概率。2016年5月至2018年11月，共有57例患者(60±8年，79%为男性，93%为白种人)被分配，完成研究的52例(每组50%)被纳入最终分析。未经调整的ess评分增加了+2.4分(95% CI +0.6至+4.2; p=0.01) in the sham-CPAP-group when compared to continuing therapeutic CPAP. The probability of superiority of therapeutic CPAP over sham CPAP was 90.4% for ESS, 90.1% for systolic, and 80.3% for diastolic blood pressure.Conclusions Patients with moderate-to-severe OSA and daytime sleepiness are still getting a substantial benefit from suboptimal CPAP adherence, albeit not as much as they might get if they adhered more. Whether a similar statement can be made for even lower adherence levels remains to be established in future trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Gaisl reports personal fees from Bayer AG (consulting), outside the submitted work.Conflict of interest: Dr. Rejmer has nothing to disclose.Conflict of interest: Dr. Thiel has nothing to disclose.Conflict of interest: Dr. Haile has nothing to disclose.Conflict of interest: Dr. Osswald has nothing to disclose.Conflict of interest: Dr. Roos has nothing to disclose.Conflict of interest: Dr. Bloch has nothing to disclose.Conflict of interest: Dr. Stradling reports personal fees from Bayer AG, personal fees from ResMed, outside the submitted work.Conflict of interest: Dr. Kohler reports personal fees from Bayer AG, grants from University of Zurich, grants from Lunge Zurich, outside the submitted work.